key: cord-0841973-kl120pw0
authors: Parashar, Nidarshana Chaturvedi; Poddar, Jit; Chakrabarti, Sasanka; Parashar, Gaurav
title: Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2
date: 2020-08-11
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2020.104497
sha: d6d47ca9e3a3576b29e33e6e0281a0514cfe192e
doc_id: 841973
cord_uid: kl120pw0

COVID-19 pandemic is rapidly advancing among human population. Development of new interventions including therapeutics and vaccines against SARS-CoV-2 will require time and validation before it could be made available for public use. Keeping in view of the emergent and evolving situation the motive is to repurpose and test the immediate efficacy of available drugs and therapeutics against COVID-19. Through this article we propose and discuss the possibility of repurposing the available nuclease resistant RNA aptamer against the nucleocapsid protein of SARS-CoV as a potential therapeutic agent for COVID-19.

for COVID-19 is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) belonging to Beta-Coronaviridae family. The symptoms of COVID-19 range from mild to severe, and include mainly fever, cough, and respiratory distress with severe cases progressing to pneumonia, hypoxemia and death (Chakrabarti et al. 2020) . Considering the emergent situation, there is a need for rapid development of theranostics to control the outbreak of COVID-19.

Though qRT PCR and antibody based diagnosis of SARS-CoV-2 are available and being utilized, there is no specific therapeutic agent or vaccine available till date. Thus, a major motive around the world is to repurpose the existing antivirals (remdesivir) and drugs (hydroxychloroquine and camostat mesylate) to test their immediate efficacy in controlling and alleviating the clinical symptoms and spread of COVID-19.

To support the initiative of repurposing and to fast track the development of probable interventions in COVID-19, we would like to propose the use of existing aptamers originally developed against SARS-CoV. Aptamers are small stretches of oligonucleotides (both DNA and RNA) of 10-100 nucleotides in length with excellent target binding specificity, cell internalization potential and no immunogenicity, suggestive of their probable direct applications under an emergent situation (Zou et al. 2019 ). It has been previously shown that anti-gp120 RNA aptamer-siRNA molecule successfully inhibited HIV-1 replication and reduced viral load both in vitro and in vivo (Zhou et al. 2013) . During literature review, to search for probable aptamer candidates previously developed against SARS-CoV protein targets, we identified DNA and nuclease resistant RNA aptamers against nucleocapsid (N) protein of SARS-CoV (Table 1) (Cho et al. 2011 , Ahn et al. 2009 ). However, no aptamer was retrieved for spike (S) protein. Both the nucleic acid aptamers have reportedly been evaluated for their diagnostic potential against the N protein of SARS-CoV, but their therapeutic utility has not been examined. The authors suggested two motifs, addition of which leads to generation of specific stem loop structure which is required for internalization. We further modified the two reported truncated RNA aptamer sequences by addition of common RNA motifs required for cell internalization at both 5' and 3' ends to create a molecule which may be fully capable of cell internalization.

Interestingly, the modified RNA aptamer 1 sequence was able to retain its native stem loop structure both for transfection motifs and N-binding domain as shown by structure analysis done (Song et al. 2020) . The aptamers needs to be further evaluated for their ability to interfere and disrupt binding between host ACE2 and RBD of spike protein both in vitro and in vivo.

Spike protein is a large membrane protein and may be targeted for prevention of virus internalization into host cell and neutralization of viral molecules by newly identified DNA aptamers. Another important aspect is that pre-and post fusion conformation changes acquired by spike protein may change its recognition sites utilized by currently identified novel aptamers thus limiting their direct potential post-internalization. However they can potentially be evaluated as a carrier molecule for delivering small RNA targeting the viral transcripts in line with our proposed approach subject to retention of native structure upon motif addition.

In conclusion, it is better to go for selection of novel aptamers against new targets, however considering the emergent situation, conserved profile of N protein, affinity of N protein towards 

RNA aptamer-based sensitive detection of SARS coronavirus nucleocapsid protein

Novel system for detecting SARS coronavirus nucleocapsid protein using an ssDNA aptamer

COVID-19 Coronavirus Pandemic

The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells

A general RNA motif for cellular transfection

The coronavirus nucleocapsid is a multifunctional protein

Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV

Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge

The author(s) declare that they have no competing interests.